56 research outputs found

    IUMPA–2: release of medroxyprogesterone acetate from the intrauterine system in the treatment of endometrial hyperplasia relative to the patient's body mass index (BMI)

    Get PDF
    CelPo pierwsze: opracowanie systemu w postaci wkładki domacicznej zawierającej octan medroksyprogesteronu do leczenia rozrostów endometrium. Po drugie: sprawdzenie dystrybucji leku zastosowanego w postaci wkładki wewnątrzmaicznej w zależności od masy ciała.Materiał i metodaBadaniem objęto 20 kobiet po menopauzie z rozpoznanym histologicznie rozrostem prostym endometrium poddanych leczeniu przy użyciu IUMPA-2 przy zastosowaniu technik endoskopowych (hysteroskopowa biopsja celowana endometrium), histologicznych (ocena bioptatów) i ultradźwiękowych (pomiary objętości systemu terapetycznego oraz endometrium).WynikiWraz ze wzrostem BMI u wszystkich pacjentek wzrastała szybkość uwalniania leku z nośnika rzutując na rzeczywisty czas leczenia, który wynosił odpowiednio od 35 do 14 dni.Wnioski1) Masa ciała chorej wpływa na szybkość uwalniania octanu medroksyprogesteronu z IUMPA-2. 2) W przypadkach chorych o wysokiej masie ciała należy rozważyć 2-krotne, sekwencyjne założenie IUMPA-2.AimFirst, to develop a system of an intrauterine diaphragm with medroxyprogesterone acetate in the treatment of endometrial hyperplasia. Second, to check the distribution of this drug depending on the patient's BMI.Materials and methodsThe study comprised a group of 20 postmenopausal patients with histologically diagnosed simple hyperplasia treated with IUMPA-2 using endoscopic techniques (hysteroscopic targeted endometrial biopsy), histological methods (bioptate assessment) and ultrasound techniques (treatment volume and endometrial measurements).ResultsIn all patients investigated the rate of medroxyprogesterone acetate release increased with BMI, which had an effect on the treatment time ranging between 35 and 14 days, respectively.Conclusions1) The BMI affects the rate of medroxyprogesterone acetate release from IUMPA-2. 2) In patients with a high BMI double (sequentially) application of a diaphragm should be considered

    Disponibilidade de fósforo de fosfato extraído de efluentes da suinocultura.

    Get PDF
    Um processo de remoção química de fósforo dos efluentes da suinocultura foi implementado na Embrapa Suínos e Aves, sendo gerado fosfato bicálcico através deste. Assim, objetivou-se determinar a disponibilidade do fósforo deste produto devido à importância econômica na alimentação de aves e suínos. O delineamento experimental foi em blocos casualizados, com nove tratamentos (controle, 0,05; 0,10; 0,15 e 0,20% de P do fosfato de dejeto e 0,05; 0,10; 0,15 e 0,20% de P do fosfato bicálcico) e 10 repetições de 28 aves (COBB, machos de um dia de idade) por unidade experimental. Aos 14 dias, três aves por unidade experimental foram abatidas para avaliar a força de uebra da tíbia. O fosfato extraído de dejetos da suinocultura continha 28,9% de Ca, 3,0% de P e 1,82% de Mg e apresentou aproximadamente 31% de disponibilidade quando comparado ao fosfato bicálcico. A process of chemical phosphorus removal with the generation of dicalcium phosphate from swine wastewater was implemented at Embrapa Swine and Poultry. Therefore, the objective of this study was to determine the phosphorus availability of this product because the potential economic importance of using this co-product as a P source for poultry and pigs. It was used a randomized block design with nine treatments (control; 0.05; 0.10; 0.15 and 0.20% P in dicalcium phosphate from swine wastewater, and 0.05, 0.10, 0.15 and 0 20% of P from dicalcium phosphate) and 10 replicates of 28 birds (one day old Cobb males) per experimental unit. After 14 days, three birds per pen were slaughtered to evaluate the breaking strength of the tibia. The dicalcium phosphate from swine wastewater contained 28.9% Ca, 3.0% P and 1.82% Mg and presented approximately 31% availability when compared to dicalcium phosphate
    corecore